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ABSTRACT
Objective Key to the clinical management of colorectal
cancer is identifying tools which aid in assessing patient
prognosis and determining more effective and
personalised treatment strategies. We evaluated
whether an experimental systems biology strategy which
analyses the susceptibility of cancer cells to undergo
caspase activation can be exploited to predict patient
responses to 5-fluorouracil-based chemotherapy and to
case-specifically identify potential alternative targeted
treatments to reactivate apoptosis.
Design We quantified five essential apoptosis-regulating
proteins (Pro-Caspases 3 and 9, APAF-1, SMAC and
XIAP) in samples of Stage II (n¼13) and III (n¼17)
tumour and normal colonic (n¼8) tissue using absolute
quantitative immunoblotting and employed systems
simulations of apoptosis signalling to predict the
susceptibility of tumour cells to execute apoptosis.
Additional systems analyses assessed the efficacy of
novel apoptosis-inducing therapeutics such as XIAP
antagonists, proteasome inhibitors and Pro-Caspase-3-
activating compounds in restoring apoptosis execution in
apoptosis-incompetent tumours.
Results Comparisons of caspase activity profiles
demonstrated that the likelihood of colorectal tumours to
undergo apoptosis decreases with advancing disease
stage. Systems-level analysis correctly predicted positive
or negative outcome in 85% (p¼0.004) of colorectal
cancer patients receiving 5-fluorouracil based
chemotherapy and significantly outperformed common
uni- and multi-variate statistical approaches. Modelling of
individual patient responses to novel apoptosis-inducing
therapeutics revealed markedly different inter-individual
responses.
Conclusions Our study represents the first proof-of-
concept example demonstrating the significant clinical
potential of systems biology-based approaches for
predicting patient outcome and responsiveness to novel
targeted treatment paradigms.
INTRODUCTION
Throughout the world, cancer is a leading cause of
death with incidence and mortality projected to
rise. Colorectal cancer is the fifth most common
form of cancer and third leading cause of cancer
related mortality. Current treatment options for
non-metastatic Stage II and III colorectal cancer
consist of surgical resection with or without
5-fluorouracil (5-FU) based chemotherapy. While
survival rates have improved through the use of
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Significance of this study
What is already known about this subject?
< There are no effective response markers to non-
targeted chemotherapies for colorectal cancer.
< Effective treatment for colorectal cancer using
traditional chemotherapies, such as 5-fluorouracil
and oxaliplatin, is hindered due to chemoresist-
ance, due in part to defective apoptosis.
< Due to its important role in cancer progression
and chemotherapy response, the intrinsic
apoptosis pathway and its associated proteins
represent both potential response markers and
points of therapeutic intervention.
What are the new findings?
< This proof of concept study indicates that
computationally modelling of non-linear
apoptosis signalling can predict response to 5-
fluorouracil based chemotherapy with high
accuracy, outperforming traditional statistical
methods based on tumoural concentrations of
proteins involved in apoptosis execution.
< Extending the model to model individual patient
responses to novel targeted therapeutics (XIAP
antagonists, proteasome inhibitors and Pro-
Caspase 3-activators) demonstrated varied
inter-individual responses to these agents.
How might it impact on clinical practice in the
foreseeable future?
< This study indicates the potential of systems
biology-based approaches in predicting patient
outcome and responsiveness to novel targeted
chemotherapies. This study highlights how such
approaches may enable oncologists to make
more informed treatment decisions, and to
provide reasoning for the inclusion of alternative,
adjuvant treatment paradigms.
< While this study focuses on the clinical potential
of this systems modelling approach in colorectal
cancer, it may have similar clinical potential
when applied to other malignancies.
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5-FU/oxaliplatin combination chemotherapy, not all patients
will benefit due to either inherent or acquired chemoresistance.1
The major molecular changes occurring during colorectal
tumourigenesis are well understood, including both epigenetic
and mutational events leading to genetic instability and the
malignant phenotype.2 A common result of these changes is
that they confer a survival advantage, leading to impaired
apoptosis and thereby contributing to uncontrollable cell
growth and resistance to traditional chemotherapies such as the
DNA damaging agents 5-FU and oxaliplatin. The intrinsic
pathway of apoptosis (figure 1) is characterised by mitochon-
drial outer membrane permeabilization (MOMP) and is acti-
vated in response to cellular stress resulting from DNA
damaging chemotherapeutics and radiation therapy.4 5 MOMP
leads to cytochrome-c and SMAC release from mitochondria
followed by apoptosome formation and caspase activation.
Specifically, cytochrome-c complexes with APAF-1, recruiting
and activating the initiator Caspase 9 which goes on to activate
the effector caspases, in particular Caspase 3 leading to the
biochemical and morphological changes characteristic of
apoptosis.6 Caspase activity is inhibited by XIAP,7 whose action
is antagonised through its interactions with the pro-apoptotic
SMAC.8 Caspase activation following cytochrome-c and SMAC
release occurs within minutes; however this rapid response is
significantly slowed when XIAP levels are high3 which may be
particularly important in cancers as XIAP is overexpressed in
a number of tumour types.9e11
Due to its importance in drug response and resistance, proteins
associated with apoptosis are frequently examined as prognostic
indicators in colorectal cancer. APAF-1,12 13 SMAC,12 14 XIAP,11
and the Caspases 315 and 916 have been shown to be differen-
tially expressed between colorectal tumours and matched normal
tissue, with increased expression of APAF-113 and SMAC14 and
decreased XIAP11 expression associating with longer patient
survival. However, it is important to note that the decision
between apoptosis and survival is not determined solely by
individual proteins but rather by the relative abundance and
interactions of multiple key apoptotic proteins. Therefore
examination of the system as a whole rather than single markers
may be more informative for patient prognosis and in identifying
targets for therapeutic intervention. Using mathematical
modelling we previously demonstrated that the decision to
undergo apoptotic cell death may be determined with high
precision using sets of ordinary differential equations (ODEs)
which reflect the non-linear processes of apoptosis execution.3
This computational systems model, APOPTO-CELL, is based on
the concentrations of five key proteins involved in mitochondria
mediated apoptosis (specifically the Pro-Caspases 3 and 9,
SMAC, APAF-1, and XIAP).3 17 Originally developed in HeLa
cells and validated experimentally in cellulo,3 the potential for
this model in the clinical setting has not yet been determined. In
this study we examined its ability to predict differences in
caspase substrate cleavage profiles between colorectal tumours
and normal tissue. Furthermore, we explored the potential for
this model to predict chemotherapy responses of dormant
mircometastatic sites to 5-FU-based chemotherapy based on an
analysis of the primary tumour site, and to identify personalised
alternative treatment options for colorectal cancer patients.
Taken together, this study is one of the first studies to validate
the clinical potential of ODE systems biology models, indicating
an important milestone in translational medical systems
biology.
MATERIALS AND METHODS
A description of quantitative western blotting and gene
expression by real time quantitative RT-PCR is provided in
Supplementary text.
Patient cohort
Colorectal cancer patient tissue was collected and stored from
the Departments of Surgery, Gastroenterology and Pathology,
Beaumont Hospital, Dublin, Ireland. Pathologic stage was
determined using Dukes’ and TNM staging. Surgically resected
colorectal tumours were obtained from 30 Stage II (n¼13) and
Stage III (n¼17) patients. Matched adjacent normal colorectal
tissue was available for 26 of these patients. Patient character-
istics are summarised in table 1. Twenty of these patients
received 5-FU- based chemotherapy, specifically 5-FU/leucovorin
(n¼17), 5-FU/oxaliplatin/leucovorin (n¼2) and 5-FU/irinotecan/
leucovorin (n¼1). Clinical follow-up was obtained through
a review of medical records by a dedicated clinical research nurse.
For classification purposes, patients without disease recurrence
and/or cancer mortality within 4 years were classified as
a ‘positive outcome’; patients who recurred/died from colorectal
cancer were classified as ‘negative outcome’. Patients with
hereditary forms of colorectal cancer were excluded. Ethical
approval has been obtained for this study by the Beaumont
Hospital Ethics (Medical Research) Committee and informed
consent was obtained from all patients. Tissue was stored for
use as snap frozen (808C) or in RNAlater (Ambion, Abington,
UK) (208C).
Statistical analysis
Wilcoxon signeddrank tests were performed to identify signif-
icant differences between tumour and normal protein expression
relative to b-actin. Correlations between mRNA and protein
expression was assessed using Pearson correlation. Associations
Figure 1 Apoptosis pathway following mitochondrial permeabilization
in response to DNA damage. Following permeabilization of the
mitochondrial outer membrane cytochrome-c and SMAC (red dots) are
released into the cytosol, initiating the apoptosis execution network
modelled by the ODE-based APOPTO-CELL model.3
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between model output parameters and patient outcome were
determined using ManneWhitney U tests.
In order to assess the ability of these proteins to predict
patient outcome, univariate discriminant analysis with cross-
validation was carried out, with each protein analysed separately
for its ability to predict outcome. To determine whether the
concentrations of APAF-1, XIAP, SMAC and Pro-Caspases 3 and
9 taken in combination associated with clinical outcome,
multivariate statistical methods were used. Stepwise forward
logistic regression was used to determine whether co-variates
such as microsatellite instability (MSI), type of chemotherapy
received and tumour differentiation were significant co-variates.
Discriminant analysis with cross-validation and principal
component analysis (PCA) were utilised, including all proteins
as variables in each method. The specificity of the computa-
tional model to correctly identify patients with negative
outcome following 5-FU based chemotherapy was determined
as described by Altman and Bland.18 Fisher ’s exact tests were
used to determine p values for the results obtained by compu-
tational modelling and discriminant analysis. PCA was carried
out in MATLAB (Mathworks, Natick, Massachusetts, USA). All
other statistical analyses were carried out using SPSS for
Windows 15.0 (SPSS Inc.). A p value of <0.05 was considered to
be statistically significant.
Mathematical modelling of caspase activation
The APOPTO-CELL model is based on a set of ODEs repre-
senting a reaction network of 53 reactions, 19 reaction partners
and 75 reaction parameters and is implemented in MATLAB.
Parameters were obtained from the literature or by independent
analysis.3 17 The model was originally developed in HeLa cells
and validated experimentally in cellulo using genetic manipula-
tions as well as by adapting the model to cancer cell lines defi-
cient in apoptosis signalling proteins.3 19 The model’s output
function (substrate cleavage by Caspase 3) is calculated by direct
integration of the effector caspase activation profile. Substrate
cleavage profiles were generated by implementing concentra-
tions of APAF1, Pro-Caspase 3, Pro-Caspase 9, XIAP and SMAC
proteins into an automated version of the model and modelled
over 300 min. At 300 min, varied caspase activation profiles were
predicted, ranging from <1% to 100%. We have previously
demonstrated that cancer cells showing <25% caspase-mediated
substrate cleavage showed no discernable signs of apoptosis.3
Therefore <25% predicted substrate cleavage at 300 min was
classified as unlikely to undergo apoptosis.
Implementation of alternative therapy regimes
into APOPTO-CELL
The systems model was extended to predict the effects of
targeted therapies on the likelihood of tumour samples to
undergo caspase activation. Therapeutics included XIAP antag-
onists,20 proteasome inhibitors,21 and Pro-Caspase 3-activating
compounds.22 XIAP antagonists were considered at initial
cytosolic concentrations of 100, 250, or 500 nM and mimicking
the behaviour of SMAC. Proteasome inhibition was modelled to
reduce the degradation rate of proteins by 10%, 50% or 100%.
Pro-Caspase 3-activating compounds were modelled at initial
concentrations of 50, 100 and 500 nM and assumed to activate
Pro-Caspase 3 by mass action kinetics with a kcat of 0.068 mM/
min.22 All simulations were modelled for 300 min following
MOMP.
RESULTS
Alterations in apoptosis protein levels in colorectal cancer
tumours
Alterations in the apoptotic machinery of cancer cells may
contribute to the decreased capacity of tumours to undergo
programmed cell death. We first examined whether APAF-1,
XIAP, Pro-Caspases 3 and 9, and SMAC proteins were differen-
tially expressed between colorectal tumours and matched
normal colorectal tissue from Stages II and III patients using
western blotting and quantitative analysis of high dynamic
range luminescence images (figure 2). Western blotting demon-
strated that there was no differential expression of b-actin
protein expression between tumour and matched normal tissue.
Colorectal tumour and normal tissue was collected and stored
between the years 2002 and 2006 according to procedures
established within the Departments of Surgery and Pathology.
Inclusion criteria were based on the following parameters:
pathologic stage of either Stages II or III, sufficient quality and
quantity of stored clinical material, and the availability of
complete clinical follow-up data for at least 4 years. Surgically
resected colorectal tumours were obtained from 13 Stage II and
17 Stage III patients who met all inclusion criteria, with
matched normal tissue available for 26 patients. Twenty of these
patients underwent 5-FU based adjuvant chemotherapy
following surgery. Patient characteristics are summarised in
table 1.
Statistical analysis of protein expression relative to b-actin
indicated significantly lower expression of APAF-1 in tumour
compared to normal tissue (Wilcoxon rank sum; p¼0.026), with
16 of 26 patients showing lower expression in tumour tissue. No
significant differences in expression of XIAP (p¼0.086), SMAC
(p¼0.929), Pro-Caspase 3 (p¼0.585) and Pro-Caspase 9
(p¼0.096) were detected.
We also addressed whether gene expression in tumours
correlated with protein expression in patients where the nucleic
acid preservative RNAlater stored tissue was available. Impor-
tantly we found no significant correlation (Pearson correlation
coefficients ranging between 0.536 and 0.029; p values ranging
from 0.171 and 0.945) between gene expression and protein
Table 1 Patient clinical characteristics
Stage II Stage III
Stages II
and III
Median age (years) 73.5 61.3 68.25
Gender
Male 9 11 20
Female 4 6 10
Chemotherapy received
Yes 3 17 20
No 10 0 10
Tumour location
Caecal 1 6 7
Ascending colon 3 2 5
Transverse colon 1 0 1
Descending colon 1 0 1
Sigmoid 3 5 8
Rectosigmoid 2 2 4
Rectal 2 2 4
Microsatellite instability status*
Yes 2 0 2
No 5 13 18
Median survival time (months)
Disease free survival 20 16 20
Overall survival 25 20 22.5
*MSI status assessable in 20/30 patients.
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concentrations (Supplementary figure 1), indicating that mRNA
levels cannot be used as a surrogate for protein expression levels.
Systems analysis indicates that apoptosis execution is impaired
with advancing disease stage
Previously we developed a computational ODE systems model
of apoptosis execution that predicts the ability of cancer cells to
undergo Caspase 3 activation following the release of
cytochrome-c and SMAC.3 To apply this model, we determined
absolute protein concentrations of APAF-1, Pro-Caspase 3, Pro-
Caspase 9, XIAP and SMAC in colorectal tumours of Stage II
(n¼13) and Stage III (n¼17) patients using quantitative western
blotting (Supplementary figure 2). Protein concentrations were
also determined in a subset of normal colorectal tissue from
Stage III colorectal cancer patients (n¼8) (Supplementary figure
3). Cytochrome-c levels were determined but not included as
very small quantities of cytochrome-c are sufficient to activate
the apoptosome by transiently binding to APAF-1.23 24 The
effects of tumour heterogeneity were addressed by comparing
concentrations of these proteins in different sections of
individual tumours, detecting little intra-individual variations
compared with inter-individual variations (Supplementary
figure 4).
Protein concentrations of APAF-1, XIAP, SMAC and Pro-
Caspases 3 and 9 were then implemented into the APOPTO-
CELL model and substrate cleavage by effector caspases was
plotted to assess for differences in the ability of tumour and
normal tissue to undergo apoptosis. In normal colorectal tissue,
the model predicted rapid caspase activation following stress-
induced MOMP (figure 3A), consistent with previous studies
showing rapid activation of caspases following MOMP.3 25 In
tumour tissue, 2 of 13 (15%) Stage II patients and 4 of 17 (24%)
of Stage III patients were predicted as unable to undergo caspase
activation (figure 3B,C; green traces), indicating a trend towards
impaired apoptosis execution with advanced disease stage.
Indeed, caspase activity was significantly higher in normal
compared with tumour tissue with mean substrate cleavage
rates (maximum slope) of 3.3762.75% and 0.4160.53%
substrate cleavage/min, respectively (ManneWhitney U test;
p<0.001). Interestingly, there was no difference in the substrate
cleavage rates between Stages II and III patients (Stage II
0.3860.46%; Stage III 0.4360.60%; Stage II vs Stage III: p>0.1;
Stage II vs Normal: p¼0.001; Stage III vs Normal: p<0.0001).
Model prediction of caspase activation correlates with
colorectal cancer patient response to chemotherapy
Resistance to chemotherapy may be in part due to resistance to
apoptosis. On the assumption that tumours released cyto-
chrome-c and SMAC following chemotherapy, we assessed
whether model predictions of caspase activation correlated with
clinical outcome in patients who received adjuvant chemo-
therapy (figure 4). Specifically, we used the model output from
Figure 2 Expression of apoptosis associated proteins in colorectal tumours and adjacent matched normal colorectal tissue. (A) Representative
western blots of tumour (T) and matched normal (N) tissue for APAF-1, XIAP, Pro-Caspase 9, Pro-Caspase-3, and SMAC. Graphs represent tumour to
normal ratios of APAF-1 (B), XIAP (C), Pro-Caspase 9 (D), Pro-Caspase 3 (E) and SMAC (F) protein expression in matched colorectal tumour and
normal tissue from 26 patients. Grey bars represent Stage II patients (n¼12), filled bars represent Stage III patients (n¼14). Line represents a Tumour/
Normal ratio of 1. Patient numbers correspond between all figures and Supplementary figures.
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data extracted from primary colorectal tumours to predict the
efficacy of 5FU-based chemotherapy on dormant micro-
metastatic sites. Twenty Stage II (n¼3) and Stage III (n¼17)
patients in this study received adjuvant 5-FU- based chemo-
therapy (table 1). Of these patients, 12 were alive with no
disease recurrence within 4 years follow-up (positive outcome)
and eight had disease recurrence or disease mortality within
4 years (negative outcome).
Figure 5 shows the predicted ability of colorectal tumours to
undergo effector caspase activation in response to MOMP for
these patients. Modelling revealed that in 4 of the 20 patients,
MOMP failed to induce any caspase activity (green traces in
figure 5). Importantly, all four patients were in the group with
negative clinical outcome. We also examined whether other
output model parameters such as the maximal rate of cleavage
and the percent substrate cleavage at which this slope was
reached varied between patients with different clinical
outcomes. Comparisons of maximum slopes of substrate
cleavage between patients with positive and negative outcome
indicated that negative outcome was associated with signifi-
cantly lower caspase activity (ManneWhitney U test; p¼0.001).
Similarly, there were significant differences in percent substrate
cleavage at maximum slope (p¼0.005) and percent substrate
cleavage at 300 min (p¼0.004).
Previous studies from our laboratory indicated that cells with
less than 25% caspase substrate cleavage following MOMP
subsequently show no morphological changes characteristic of
apoptosis.3 Therefore, a threshold of 25% caspase substrate
cleavage within 300 min of cytochrome-c release was used to
examine the ability of the model to predict chemotherapy
responsiveness. Using this criterion, apoptosis was predicted in
11 of 12 patients with positive outcome (figure 5A), while
insufficient caspase activation was predicted in 6 of 8 patients
with negative outcome (figure 5B); a predictive rate of 85% (17/
20; Fischer exact test, p¼0.005) and a specificity of 91.7%. In
order to address whether the prediction rate of the model is
affected by confounding variables such as the type of chemo-
therapy received or MSI status we performed a multivariate
logistic regression. Of those patients who received chemo-
therapy, none of those assessed displayed MSI. Covariates in the
analysis included model prediction of caspase activation, MSI
status, tumour stage, tumour differentiation, age and gender. Of
these co-variates, only model output was a significant predictor
of patient outcome (OR¼0.03, p¼0.008).
To evaluate whether the above systems modelling results out-
perform statistical approaches commonly used in prognostic
marker studies, we first examined the relationship between
individual protein concentrations and response to therapy.
Univariate statistical analysis indicated significantly higher
XIAP expression in patients with negative outcome
(ManneWhitney U test; p¼0.031) and significantly higher
SMAC expression in patients with positive outcome (p¼0.025),
however discriminant analysis of these proteins alone indicate
that neither individual proteins could sufficiently predict patient
outcome on its own (p¼0.170 and 0.197 respectively). None of
the other proteins showed significant differences between
patients with positive or negative outcome. In addition, we
assessed whether expression of Pro-caspase 8, a key component
of the extrinsic apoptotic pathway was associated with patient
outcome. Western blotting indicated that there was no signifi-
cant difference in Caspase 8 levels between normal and tumour
tissue (Supplemental figure 5). Univariate statistics indicated
that there was no difference between patients with positive and
Figure 3 Systems model predicts decreased apoptosis execution with advancing disease stage. Model output in normal colorectal tissue (n¼9) (A),
(B) Stage II (n¼13) (B), and Stage III (n¼17) (C) colorectal tumours following implementation of protein concentrations. Graphs represent model output
of caspase activation (per cent substrate cleavage) over time. Green lines indicate patients with no caspase activation predicted.
Figure 4 Schematic representation of study design. The APOPTO-CELL
systems model was utilised to predict clinical outcome in colorectal
cancer patients receiving 5-FU-based chemotherapy.
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negative outcome (p¼0.234) and discriminant analysis indicated
that Procaspase 8 expression alone was not able to predict
patient outcome following chemotherapy (p¼0.298).
We next evaluated the ability of two multivariate statistical
approaches, discriminant analysis and PCA, to determine the
ability of proteins in combination to discriminate between
patient outcomes. Discriminant analysis was employed to
determine whether protein concentrations of APAF-1, XIAP,
SMAC and Pro-Caspases 3 and 9 taken together were able to
predict patient outcome. This method demonstrated while 75%
(15/20) of patients were correctly classified, this method of
analysis did not reach statistical significance (p¼0.109). We also
employed PCA to investigate whether a set of linear combina-
tions of protein concentrations could distinguish between
negative and positive outcomes. While 70% of the variance in
the patient data set could be explained by the two major prin-
cipal components (Supplementary figure 6A), no clustering of
patient data with similar clinical outcome was observed
(Supplementary figure 6B). Taken together these results indicate
that the multivariate statistical approaches are outperformed in
differentiating between patient outcomes by a systems
approach which takes into account both signalling network
topology and non-linear signalling dynamics.
Systems analysis approach as a predictive tool in determining
individual responses to novel adjuvant therapies targeting
apoptosis
The ability of this model to identify patients as unlikely to
respond to 5-FU-based chemotherapy indicated that lack of
chemotherapy responsiveness may be attributed to the inability
of dormant metastatic tumour cells to efficiently execute
apoptosis following MOMP. Therefore drugs which target the
apoptosis pathway downstream of cytochrome-c release may
have potential clinical utility in patients predicted as unlikely to
Figure 5 Model output correlates with treatment responses in colorectal cancer patients. Substrate cleavage profiles in individual colorectal cancer
patients receiving chemotherapy with positive (n¼12) (A) and negative outcome (n¼8) (B). Graphs represent model output of caspase activation (per
cent substrate cleavage) over time. Green lines indicate patients with no caspase activation predicted; dashed line indicates threshold of 25% substrate
cleavage.
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respond to traditional chemotherapies. XIAP antagonists might
overcome chemoresistance by freeing processed, active caspases
from their inhibitor XIAP.20 Proteasome inhibition results in
decreased protein degradation, a process important for proteins
subject to enforced proteasomal degradation, in particular active
Caspase 3 and 9. Direct activators of Pro-Caspase 3 result in
activation of Caspase 3 independent of upstream Caspase 9,22
thereby circumventing chemotherapy resistance due to
decreased APAF-1 levels or high levels of XIAP.
We expanded the systems model to predict whether these
drugs could re-establish Caspase 3 activity in those patients
initially identified as unlikely to undergo apoptosis following
chemotherapy (<25% substrate cleavage after 300 min). Inter-
estingly, the model predictions indicated a marked variability in
response to these agents between individual patients (figure 6).
Proteasome inhibition and Pro-Caspase 3-activating compounds
were predicted to be effective only in a subgroup of patients. In
contrast, XIAP antagonists were found to be effective in all
patients, yet at greatly varying concentration ranges, indicating
the potential of this approach to provide guidance for person-
alised treatments for colorectal cancer patients.
DISCUSSION
Despite numerous studies aimed at identifying prognostic
markers for colorectal cancer, tumour staging remains the key
prognostic indicator, with other possible indicators including
microsatellite instability26 and tumour location.27 In patients
with non-metastatic colorectal cancer, adjuvant chemotherapy
plays an important role in treatment: however the benefits even
among this group are not entirely clear. Five year survival of
Stage II patients is approximately 75% with surgery alone,
therefore at maximum only 25% of these patients will poten-
tially benefit from adjuvant chemotherapy. In Stage III patients,
survival rates are low even with the introduction of 5-FU in
combination with either oxaliplatin1 or the topoisomerase I
inhibitor irinotecan.28 Chemoresistance limits effectively
treating this disease, especially in more advanced disease stages.
Identifying markers for therapy response is an integral compo-
nent in decreasing mortality, as it will lead to personalised or less
toxic therapies by differentiating between patients likely to
respond to current chemotherapies and those more likely to
respond to new targeted therapies. Considering the implications
of dysregulated apoptosis in cancer, apoptotic regulatory
proteins are frequently examined as potential biomarkers for
patient prognosis and response to chemotherapy.29 The majority
of these studies focused on individual proteins or selections of
proteins, yet attempts to incorporate system approaches taking
into account signalling network topology as well as non-linear
signalling dynamics have not yet been performed. This study
highlights the advantages of systems biology approaches not
only as tools for predicting chemotherapy response, but more
importantly for determining alternative treatment strategies for
patients unlikely to respond to traditional chemotherapeutics.
From the onset of our study, ODE-based modelling of effector
caspase activation demonstrated that matched normal colon
tissue from colorectal cancer patients would undergo rapid and
complete substrate cleavage following MOMP. In comparison,
tumours were predicted to have a diminished capacity to
undergo substrate cleavage, in agreement with experimental
evidence demonstrating decreased apoptosis susceptibility in
tumour tissue compared with normal tissue.30 The molecular
mechanisms leading to altered protein levels of key apoptosis
proteins in colorectal cancer include not only genetic but also
epigenetic modifications.31 For example, apaf1 is hyper-
methylated in certain cancers32 and is a target of the histone
deacetylase HDAC2,33 both of which lead to decreased APAF1
expression. Interestingly, comparisons of the mRNA levels and
protein expression of the proteins examined showed little
correlation. The lack of correlation between mRNA and protein
levels highlights the importance of analysing protein levels in
systems approaches which model pathways based on protein
concentrations and their interactions. Similarly, other clinical
studies have shown discordance between gene expression and
protein production in prostate and lung cancers34 35 with the
question remaining as to why these differences exist. The
mechanisms underlying translational regulation of these
proteins may be important, including the initiation of cap-
independent translation, which may allow for the translation of
proteins which would normally be turned off in response to
stress conditions.36 In addition, miRNAs may negatively regu-
late translation, thereby leading to the decreased translation of
protein from the mRNA template, independent of mRNA
degradation.37 Importantly, post-translational mechanisms such
as different rates of protein degradation by the proteasome and
cathepsins may also contribute to the lack of concordance
between protein and mRNA expression.
As previously noted, the proteins examined here have previ-
ously been explored as prognostic markers in colorectal cancer.
Studies have shown higher expression of caspase 3, SMAC and
XIAP in colorectal tumours compared to matched normal
tissue,12 15 while Caspase 9 was present in lower levels in
tumours,16 with only XIAP, SMAC and APAF-1 having potential
prognostic value using immunohistochemistry. Xiang et al
demonstrated that expression of XIAP in tumours is associated
Figure 6 Predicting the effects of
alternative, targeted treatment
strategies in colorectal cancer patients.
The APOPTO-CELL model was
expanded to include the effects of XIAP
antagonists (green bars), proteasome
inhibition (blue bars) and direct
activation of Pro-Caspase 3 (red bars).
The effects of these drugs on caspase
activation profiles in patients with
<25% substrate cleavage predicted.
Panels represent individual patients.
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with poor prognosis.11 Decreased expression of SMAC was
associated with poor prognosis,14 while increased expression of
APAF-1 has been associated with better prognosis.13 38 39 Using
quantitative Western blotting techniques, we confirmed these
previous studies, with patients with negative outcome following
5-FU-based chemotherapy having higher XIAP and lower SMAC
concentrations. Yet as single markers these proteins were unable
to discriminate between patients with negative and positive
outcomes. Using the computational model of caspase activation
however, we were able to predict response in patients treated
with 5-FU-based chemotherapy in 85% (p¼0.004) of patients,
identifying those not responding to chemotherapy with 91.7%
specificity. Apoptosis defects upstream of MOMP such as bax
gene deletions40 were not taken into account, however, they
may also contribute to apoptosis resistance. Despite this limi-
tation, the APOPTO-CELL approach was superior to the
discriminant statistical analysis for classifying patients. Our
study therefore demonstrates the suitability of a systems
approach for predicting treatment responses, and its advantages
over more traditional statistical approaches.
Importantly, our study demonstrates the feasibility of analy-
sing the ability of primary tumour cells to undergo caspase
activation in predicting responses of dormant micrometastatic
cells to chemotherapy. By using primary tumour tissue, this
study is limited in that it fails to take into account additional
cellular changes occurring during metastasis. Given the difficul-
ties of procuring sufficient quality tissue from metastatic sites,
the high accuracy at which the APOPTO-CELL is able to predict
outcome from the primary site is therefore an important finding.
Furthermore, among those patients with negative outcome
examined here, only 3 of 8 went on to have second line
chemotherapy, all of whom went on to die from disease within
the 4 year follow-up period. Therefore no real conclusions can be
drawn as to the ability of the model to predict responses to
second line therapy following recurrence. Future studies aimed
specifically at validating the clinical utility of the APOPTO-
CELL model in predicting combination therapy responses in
metastatic CRC would shed light on the ability of the model to
predict response to not only traditional chemotherapies, but also
to targeted therapies currently in clinical practice such as the
bevacizumab or cetuximab.
While 5-FU based adjuvant chemotherapies are currently the
standard of care for colorectal cancer, survival rates still remain
low and there is a pressing need to identify alternative treat-
ments strategies for these patients. The present study highlights
the importance systems biology based models may have in
determining alternative treatment options which may prove
to be effective strategies either alone or in combination
with standard chemotherapies in patients who respond poorly
to 5-FU based standard therapies. XIAP, SMAC, APAF-1, and
Pro-Caspases 3 and 9 as well as the proteasome have been
explored widely as viable therapeutic targets,41e43 and drugs
targeting these proteins are in clinical and pre-clinical
testing.44e46 The model indicated that the ability of these
different drug classes to re-activate apoptosis may vary across
patients, both in terms of drug type as well as effectiveness of
each drug at fixed concentrations. Early stage clinical trials
testing these novel agents may therefore avail of the approach
taken in this study, and target individual patients for the
inclusion into a trial. Limiting this however will be the paucity
of suitable surgical resection samples with regard to both
quantity and quality for protein analysis for immunoblotting as
well as the time consuming nature of quantitative western
blotting techniques. Therefore refinement and validation of this
systems approach to potentially accommodate routine immu-
nohistopathology data may represent an important future
development. The simplicity of this approach, determining the
protein levels of five key apoptosis proteins in resected tumour
material relative to a HeLa cell standard, in combination with the
APOPTO-CELL online tool17 allows for easy incorporation into
phase 2 clinical trials. While this approach has only so far been
studied in colon cancer, it may be applied to a variety of cancers.
In conclusion, we here present the first proof-of-concept
translational study examining the application of non-linear
systems models in a clinical setting. We demonstrate that the
APOPTO-CELL model has significant potential for use as a tool
in identifying colorectal cancer patients unlikely to benefit from
5-FU based chemotherapy. In the future, such approaches may
enable oncologists to make more informed treatment decisions,
and to provide reasoning for the inclusion of alternative,
adjuvant treatment paradigms.
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